File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Schizophrenia with movement disorder prior to treatment

TitleSchizophrenia with movement disorder prior to treatment
Authors
Issue Date2002
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schres
Citation
The 11th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, 24 February-1 March 2002. In Schizophrenia Research, 2002, v. 53 n. 3 suppl. 1, p. 55, abstract A67 How to Cite?
AbstractMovement disorders are present in a subgroup of patients with schizophrenia prior to exposure to antipsychotic treatment, and may have implications for treatment response and outcome. As part of the Hong Kong First-Episode Psychosis Study, patients were assessed with the PANSS, Simpson–Angus, Barnes Akathisia and AIMS scales at presentation. We identified nine patients with movement disorders prior to any treatment. These patients and a comparison group of 36 patients with no movement disorder prior to treatment were reassessed at two later time points (mean 8 and 26 weeks later). At presentation, patients with movement disorders had higher negative symptom factor scores (0–6 scoring, 7 items, mean 14.6 vs. 9.3, p = 0.03). At the second and third assessments, all patients were being treated with antipsychotic medication (mean doses 438 and 302 mg CPZ equivalents), with no difference between groups at either time point. Among patients with movement disorders prior to treatment, these resolved in 3/9 at assessment two, and in 6r9 at assessment three. Considering all three time points, patients with movement disorders at baseline had higher total PANSS (p = 0.005), negative symptom factor (p = 0.003) and cognitive symptom factor (p = 0.04) scores. Positive symptom factor scores did not differ. In never-medicated patients with movement disorders, specific domains of symptomatology appear to be different when compared over time with patients who do not have movement disorders prior to treatment.
DescriptionThis journal suppl. entitled: XIth Biennial Winter Workshop on Schizophrenia
Persistent Identifierhttp://hdl.handle.net/10722/105518
ISSN
2015 Impact Factor: 4.453
2015 SCImago Journal Rankings: 2.304

 

DC FieldValueLanguage
dc.contributor.authorHoner, WGen_HK
dc.contributor.authorlANG, DLen_HK
dc.contributor.authorChan, RCKen_HK
dc.contributor.authorChen, EYHen_HK
dc.date.accessioned2010-09-25T22:37:26Z-
dc.date.available2010-09-25T22:37:26Z-
dc.date.issued2002en_HK
dc.identifier.citationThe 11th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, 24 February-1 March 2002. In Schizophrenia Research, 2002, v. 53 n. 3 suppl. 1, p. 55, abstract A67en_HK
dc.identifier.issn0920-9964en_HK
dc.identifier.urihttp://hdl.handle.net/10722/105518-
dc.descriptionThis journal suppl. entitled: XIth Biennial Winter Workshop on Schizophrenia-
dc.description.abstractMovement disorders are present in a subgroup of patients with schizophrenia prior to exposure to antipsychotic treatment, and may have implications for treatment response and outcome. As part of the Hong Kong First-Episode Psychosis Study, patients were assessed with the PANSS, Simpson–Angus, Barnes Akathisia and AIMS scales at presentation. We identified nine patients with movement disorders prior to any treatment. These patients and a comparison group of 36 patients with no movement disorder prior to treatment were reassessed at two later time points (mean 8 and 26 weeks later). At presentation, patients with movement disorders had higher negative symptom factor scores (0–6 scoring, 7 items, mean 14.6 vs. 9.3, p = 0.03). At the second and third assessments, all patients were being treated with antipsychotic medication (mean doses 438 and 302 mg CPZ equivalents), with no difference between groups at either time point. Among patients with movement disorders prior to treatment, these resolved in 3/9 at assessment two, and in 6r9 at assessment three. Considering all three time points, patients with movement disorders at baseline had higher total PANSS (p = 0.005), negative symptom factor (p = 0.003) and cognitive symptom factor (p = 0.04) scores. Positive symptom factor scores did not differ. In never-medicated patients with movement disorders, specific domains of symptomatology appear to be different when compared over time with patients who do not have movement disorders prior to treatment.-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/schresen_HK
dc.relation.ispartofSchizophrenia Researchen_HK
dc.rightsSchizophrenia Research. Copyright © Elsevier BV.en_HK
dc.titleSchizophrenia with movement disorder prior to treatmenten_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0920-9964&volume=53&issue=3&spage=55&epage=&date=2002&atitle=Schizophrenia+with+movement+disorder+prior+to+treatmenten_HK
dc.identifier.emailChan, RCK: ckrchan@graduate.hku.hken_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.hkuros73391en_HK
dc.identifier.volume53en_HK
dc.identifier.issue3 suppl. 1en_HK
dc.identifier.spage55, abstract A67en_HK
dc.identifier.epage55, abstract A67-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats